

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EDDING GENOR GROUP HOLDINGS LIMITED**

**亿腾嘉和醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6998)**

## **VOLUNTARY ANNOUNCEMENT**

### **COMPLETION OF THE FIRST SUBJECT DOSING IN PHASE IB/II CLINICAL TRIAL OF GB268**

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Group about the latest business advancement of the Group.

The board of directors of the Company is pleased to announce that the first subject dosing has been successfully completed on 5 August 2026 in the Phase Ib/II clinical trial of GB268, the Company’s highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody, for the treatment of locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer.

The study comprises monotherapy, immunotherapy in combination with chemotherapy and immunotherapy in combination with antibody-drug conjugates. The primary endpoints of the study are to evaluate the safety and tolerability of GB268 in combination therapy, including dose-limiting toxicity (DLT), and to evaluate the preliminary anti-tumor activity of GB268 as monotherapy and in combination with different treatment regimens in the respective breast cancer populations.

The clinical protocol covers the full course of treatment from first-line to later-line settings, marking the first step in comprehensively expanding the application scope of GB268. In the future, the Company also expects to initiate multiple combination therapy clinical studies in additional advanced solid tumor indications. The Phase I clinical data for GB268 monotherapy are planned to be presented at the European Society for Medical Oncology (ESMO) congress in the fourth quarter of 2026.

By Order of the Board of Directors  
**Edding Genor Group Holdings Limited**  
**Mr. Ni Xin**  
*Chairman and Executive Director*

Hong Kong, 6 August 2026

*As of the date of this announcement, the Board of directors comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.*